Previous research has demonstrated that the ratio of adverse event reporting of rhabdomyolysis associated with simvastatin stratified by concomitant use of CYP3A4 inhibitor was 6.3 [25]. This evidence concerns the gene CYP3A4 and rhabdomyolysis.